{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.135","value":"0.050"},{"groupId":"OG001","spread":"0.201","value":"0.039"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"484"},{"groupId":"OG001","value":"492"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.402","value":"0.104"},{"groupId":"OG001","spread":"0.257","value":"0.075"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.126","value":"0.088"},{"groupId":"OG001","spread":"0.232","value":"0.086"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"281"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.119","value":"0.078"},{"groupId":"OG001","spread":"0.299","value":"0.115"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.231","value":"0.121"},{"groupId":"OG001","spread":"0.163","value":"0.109"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"264"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.171","value":"0.192"},{"groupId":"OG001","spread":"0.267","value":"0.205"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"257"},{"groupId":"OG001","value":"251"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"484"},{"groupId":"OG001","value":"492"}],"units":"Participants"}],"description":"Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in Eosinophils","type":"SECONDARY","unitOfMeasure":"10^9 cells/liter"}